Temozolomide-based chemotherapy represents an incremental improvement in the
treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset …

Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and
the most frequent primary tumor of the central nervous system. The median survival of newly …

Purpose: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole
tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3 …

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective
drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma …

Despite aggressive treatment, the high-grade malignant glioma (specifically, anaplastic
astrocytoma and glioblastoma multiforme) have a poor prognosis with current methods …

Abstract Purpose of Review Temozolomide is a first-line treatment for newly diagnosed
glioblastoma. In this review, we will examine the use of temozolomide in other contexts for …

This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated
the activity of an extended, dose-dense temozolomide regimen in patients with …

Protracted low dose temozolomide (75 mg/m 2/day on days 1–21 of 28 days) offers potential
advantages over standard temozolomide schedules (200 mg/m 2/day on days 1–5 of 28 …

Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) which have a
combined incidence of 5–8/100,000 population, represent the most common primary central …

Glioblastoma multiforme and anaplastic astrocytoma are the most common primary central
nervous system malignancies and are the major cause of morbidity/mortality despite …